<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551756</url>
  </required_header>
  <id_info>
    <org_study_id>CQ 17-11-009</org_study_id>
    <nct_id>NCT03551756</nct_id>
  </id_info>
  <brief_title>Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease</brief_title>
  <official_title>Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CirQuest Labs, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CirQuest Labs, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of Biomarkers in Patients with Decompensated Heart Failure and Underlying Coronary
      Artery Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-sectional, single center exploratory study of plasma biomarker levels in
      adults with decompensated heart failure and significant underlying coronary artery disease as
      compared with age-matched healthy controls. Subjects will not receive a therapeutic treatment
      as part of this study and will undergo a single blood draw.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker assessment</measure>
    <time_frame>1 day</time_frame>
    <description>Exploratory biomarker analysis</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Heart Failure &amp; Coronary Artery Disease</arm_group_label>
    <description>Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Adult</arm_group_label>
    <description>Biomarker assessment in 20 healthy age-matched subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker Assessment</intervention_name>
    <description>Exploratory Biomarker Analysis for cardiac patients versus healthy adults</description>
    <arm_group_label>Healthy Adult</arm_group_label>
    <arm_group_label>Heart Failure &amp; Coronary Artery Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        100 subjects with the study diagnosis and 20 healthy age-matched subjects, no restrictions
        on gender, race, or ethnicity
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1: Heart Failure with Coronary Artery Disease Subjects

          -  Symptomatic heart failure (≥ 3 months) with most recently documented LVEF ≤ 40% (Echo
             must have been completed in last 12 months prior to enrollment.)

          -  Significant underlying coronary artery disease as evidenced by:

          -  previous myocardial infarction

          -  prior coronary artery bypass graft

          -  50% coronary stenosis of one or more arteries and/or

          -  history of percutaneous coronary intervention with or without stenting

          -  Age 18 years or older at the first screening visit

        Group 2: Healthy Subjects

        • Age 18 years or older at the first screening visit and within 20% of mean age of Group 1
        Subjects

        Exclusion Criteria:

        Group 1:

          -  Documented history of &quot;severe&quot; valvular disease

          -  Documented history of atrial fibrillation, ventricular fibrillation or ventricular
             tachycardia.

          -  Recent or current use of anticoagulant medications such as fXa inhibitors, direct
             thrombin inhibitors, vitamin K antagonists, or heparin. (within 1 month of screening)

        Group 2:

          -  Known significant cardiovascular or hematological condition

          -  Recent or current use of anticoagulant medications such as fXa inhibitors, direct
             thrombin inhibitors, vitamin K antagonists, or heparin. (within 1 month of screening)

          -  Recent cold or flu symptoms, respiratory infection or surgery (within 2 weeks of
             screening)

          -  History of Asthma

          -  History of peptic ulcers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa K. Jennings, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CirQuest Labs, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol E Hendrix, MSN, RN</last_name>
    <phone>901-866-1700</phone>
    <email>chendrix@cirquestlabs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edward Hord, BSN, RN</last_name>
    <phone>901-866-1700</phone>
    <email>ehord@cirquestlabs.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latonya Been</last_name>
      <phone>904-244-4520</phone>
      <email>Latonya.Been@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Dominick J Angiolillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Dragutsky</last_name>
      <phone>901-271-1000</phone>
      <email>brian.dragutsky@sterncardio.com</email>
    </contact>
    <contact_backup>
      <last_name>Rishi Bhula</last_name>
      <phone>901-271-1000</phone>
      <email>rishi.bhula@sterncardio.com</email>
    </contact_backup>
    <investigator>
      <last_name>Frank A McGrew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CirQuest Labs, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol E Hendrix, MSN, RN</last_name>
      <phone>901-866-1700</phone>
      <email>chendrix@cirquestlabs.com</email>
    </contact>
    <contact_backup>
      <last_name>Edward Hord, BSN, RN</last_name>
      <phone>901-866-1700</phone>
      <email>ehord@cirquestlabs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa K Jennings, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rick Alleman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

